Seizing a Pap smear to catch a criminal? Ethical issues of forensic use of medical biobanks
By Nina de Groot,
Journal of Medical Ethics blog
| 06. 09. 2020
In our paper, we discuss pressing problems with respect to confidentiality, trust, autonomy and justice.
A couple of years ago, during my studies, I assisted with a surgical removal of a benign uterine tumor at a small local hospital. As not much else was happening that day, I decided to follow the tumor out of the operation room all the way down to the pathologist in the basement. After examining the tumor sample, the pathologist opened a couple of doors to the storage rooms. That’s when I found out about the huge archives of tissue material that comprised most of the tiny hospital’s basement. “Oh, but this is not everything”, the pathologist told me, “we keep most of the tissue samples in storage boxes next to the highway”. As the tissue sections were to be stored for 115 years, the archives were bursting at the seams.
Ever since, the vast amount of little human parts scattered across the country has fascinated me. In the years to follow, I would see dusty moving boxes in corridors, high-tech automatically operated storages, and tanks of liquid nitrogen in a hospital’s parking lot. Filled with blood, sperm, tumor samples...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...